Abstract
India ranks high for prevalence of diabetes and the treatment of diabetes without any side effects is still challenging. Though herbal remedies help reduce the side effect, proper standardization of phytochemical which prove as a bioactive compound, its proper dose and clinical trials are lacking. In our investigation, we studied the binding mechanism of the secondary metabolites of Syzygium cumini, their in vitro antidiabetic activity and the number of phytochemicals present. In silico study revealed that ellagic acid has a potential to modulate the carbohydrate metabolizing enzyme activity showing higher affinity for the enzymes with much lesser binding energy, -4.73 kcal/mol for alpha amylase, -4.87 kcal/mol for beta-glucosidase, -4.79 kcal/mol for glycogen synthase kinase, -4.18 kcal/mol for glucokinase and -4.49 kcal/mol for alpha-glucosidase. In vitro-Alpha amylase inhibitory activity assay showed that ethanol extract has the highest value of percent inhibition (73.33%) as compared to standard drug Acarbose (65.99%). Finally, TLC analysis cleared that ethanol extract contains five compounds one of which may be a bioactive compound, ellagic acid. Further purification and characterization of the ellagic acid is needed.
Highlights
IntroductionIndia is known as the “Diabetes capital of the world” with high prevalence of diabetes (more than 62 million) in the country
India is known as the “Diabetes capital of the world” with high prevalence of diabetes in the country
Result and Discussion In silico - molecular docking analysis Molecular docking analysis of the secondary metabolites found in the S. cumini with the major enzymes those incorporate into the diabetes mellitus were performed to gain insight into the potential antidiabetic activity of these compounds
Summary
India is known as the “Diabetes capital of the world” with high prevalence of diabetes (more than 62 million) in the country. Every fifth diabetes patient occurs in the world is an Indian. In India up to 79.4 million people will affect adversely with diabetes by 2030 (Joshi et al, 2007; Kaveeshwar et al, 2004). The two major types of diabetes viz. Type I diabetes (T1D), an autonomous disease cause due to insufficient or no production of insulin in the body and Type II diabetes (T2D) in which progressive insulin resistance is developed. Type II diabetes has a higher dominance worldwide and is a serious growing public health problem. Apart from the health consequences, diabetes is one of the economic burdens, including cost of treatment of the disease and its associated complications, increased mortality and morbidity cost and the cost required for informal care etc. Apart from the health consequences, diabetes is one of the economic burdens, including cost of treatment of the disease and its associated complications, increased mortality and morbidity cost and the cost required for informal care etc. (Hex et al, 2012)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
